학술논문

Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial
Document Type
Article
Source
In Annals of Oncology March 2024 35(3):293-301
Subject
Breast tumor
Language
ISSN
0923-7534